Know Cancer

or
forgot password

A Randomized Phase III Trial of Vinorelbine Versus Gemcitabine and Carboplatin for Elderly Patients With Advanced Non-Small Cell Lung Cancer


Phase 3
65 Years
N/A
Open (Enrolling)
Both
Non-Small Cell Lung Cancer

Thank you

Trial Information

A Randomized Phase III Trial of Vinorelbine Versus Gemcitabine and Carboplatin for Elderly Patients With Advanced Non-Small Cell Lung Cancer


Inclusion Criteria:



- Patients with pathologically confirmed, advanced(clinical stage IIIB or IV) NSCLC

- No previous chemotherapy history

- Age ≥ 65 years

- ECOG performance status ≤ 2

- Adequate marrow function (ANC ≥ 2,000/mm3, platelet ≥ 100,000/mm3), renal and liver
function (total bilirubin < 2.0 mg/dL, AST/ALT levels < 3 × the upper limit of
normal, serum creatinine < 2.0 mg/dL)

- Patients with informed written consent

Exclusion Criteria:

- Patients with other major illness(active infection, severe heart disease, concomitant
malignancy, etc)

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Principal Investigator

Young Jin Yuh, M.D.

Investigator Role:

Principal Investigator

Authority:

Korea: Food and Drug Administration

Study ID:

INJE05-06

NCT ID:

NCT00265694

Start Date:

Completion Date:

Related Keywords:

  • Non-Small Cell Lung Cancer
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

Name

Location